N-boc-(乙基氨基)乙醛 | 315718-06-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-boc-(乙基氨基)乙醛
• 英文名称: tert-butyl ethyl(2-oxoethyl)carbamate
• 英文别名: tert-butyl N-ethyl-N-(2-oxoethyl)carbamate
• CAS: 315718-06-0
• 化学式: C₉H₁₇NO₃
• 分子量: 187.239
• InChiKey: FUPPSSYQZOOVBZ-UHFFFAOYSA-N

物化性质

• 沸点：
  238.0±19.0 °C(Predicted)
• 密度：
  1.011±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  -20°C，保存在惰性气体中。

反应信息

• 作为反应物：
  描述：

  N-boc-(乙基氨基)乙醛 在 bis-triphenylphosphine-palladium(II) chloride 、 ammonium hydroxide 、 potassium phosphate 、 N-碘代丁二酰亚胺 、 sodium acetate 、 溶剂黄146 作用下， 以 2-甲基四氢呋喃 、 甲醇 、 水 、 异丙醇 为溶剂， 反应 83.5h， 生成 tert-butyl ((4-amino-7-(1H-pyrazol-3 -yl)-1H-imidazo[4,5-c] quinolin-2-yl)methyl)(ethyl)carbamate dichloroacetic acid salt
  参考文献：
  名称：

  咪唑融合 2-氨基喹啉 NLRP3 激动剂收敛合成的偶联-缩合策略

  摘要：

  报道了 NLRP3（核苷酸结合域和富含亮氨酸重复序列的蛋白 3）激动剂 BMS-986299 的收敛途径的发展。该合成依赖于关键的 Miyaura 硼酸化和碘咪唑与邻氨基氯芳烃之间的串联 Suzuki-Miyaura 偶联，然后通过酸介导的环化反应得到氨基喹啉核。随后的 Boc 裂解和区域选择性酰化提供了目标化合物。介绍了获得碘咪唑中间体的两条路线，以及通过 Negishi 偶联合成邻氨基氯芳烃。与线性使能合成相比，收敛的六步路线导致过程质量强度降低 80%。

  DOI：

  10.1021/acs.joc.2c02395
• 作为产物：
  描述：

  乙基(2-羟基乙基)氨基甲酸叔丁酯 在 2,2,6,6-四甲基哌啶氧化物 、 碘苯二乙酸 作用下， 生成 N-boc-(乙基氨基)乙醛
  参考文献：
  名称：

  Rigorous control of vesicle-forming lipid pKa by fluorine-conjugated bioisosteres for gene-silencing with siRNA

  摘要：

  While the influence of pK(a) provided by amine-containing materials in siRNA delivery vectors for use in genesilencing has been widely studied, there are little reports in which amine pK(a) is controlled rigorously by using bioisosteres and its effect on gene-silencing. Here, we report that amine pK(a) could be rigorously controlled by replacement of hydrogen atom(s) with fluorine atom(s). A series of mono- and di-amine lipids with a different number of fluorine atoms were synthesized. The pK(a) of the polyamine lipids was shifted to a lower value with an increase in the number of fluorine atoms. The optimal pK(a) for high gene-silencing efficiency varied according to the number of amine residues in the polyamine lipid. Whereas the endosomal escape ability of mono-amine lipid-containing lipid vesicles (LVs) depended on the pK(a), that of all tested di-amine lipid-containing LVs showed equal membrane-destabilizing activity. LVs showing moderately weak interactions with siRNA facilitated cytoplasmic release of siRNA, resulting in strong gene-silencing. These findings indicate that appropriate amine pK(a) engineering depending on the number of amines is important for the induction of effective RNA interference.

  DOI：

  10.1016/j.jconrel.2018.12.044

文献信息

• BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS
  申请人：Kondo Kazumi

  公开号：US20110071084A1

  公开（公告）日：2011-03-24

  The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is represented by general formula (1) wherein R 1 represents a —CO—(CH 2 ) n —COR 2 group (wherein n is an integer of 1 to 4, and R 2 is (2-1) a hydroxy group; (2-2) a lower alkoxy group optionally substituted with a hydroxy group, a lower alkanoyl group, a lower alkanoyloxy group, a lower alkoxycarbonyloxy group, a cycloalkyloxycarbonyloxy group, or 5-methyl-2-oxo-1,3-dioxo-4-yl; or (2-3) an amino group optionally substituted with a hydroxy-lower alkyl group), or the like.

  本发明提供了一种苯哌啶化合物，可以长时间维持托瑞那汀的血药浓度，从而实现所需的药效。本发明的苯哌啶化合物由通式（1）表示，其中R1代表一个—CO—(CH2)n—COR2基团（其中n为1至4的整数，R2为(2-1)一个羟基；(2-2)一个可选择地取代有羟基、较低烷氧基、较低烷酰基、较低烷酰氧基、较低烷氧羰氧基、环烷氧羰氧基或5-甲基-2-氧代-1,3-二氧代-4-基的较低烷氧羰氧基；或(2-3)一个可选择地取代有羟基较低烷基基团的氨基），等等。
• Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6
  作者：Yudao Shen、Magdalena M. Szewczyk、Mohammad S. Eram、David Smil、H. Ümit Kaniskan、Renato Ferreira de Freitas、Guillermo Senisterra、Fengling Li、Matthieu Schapira、Peter J. Brown、Cheryl H. Arrowsmith、Dalia Barsyte-Lovejoy、Jing Liu、Masoud Vedadi、Jian Jin

  DOI：10.1021/acs.jmedchem.6b01033

  日期：2016.10.13

  Well-characterized selective inhibitors of protein arginine methyltransferases (PRMTs) are invaluable chemical tools for testing biological and therapeutic hypotheses. Based on 4, a fragment-like inhibitor of type I PRMTs, we conducted structure–activity relationship (SAR) studies and explored three regions of this scaffold. The studies led to the discovery of a potent, selective, and cell-active dual

  蛋白质精氨酸甲基转移酶（PRMT）的特征明确的选择性抑制剂是测试生物学和治疗假设的宝贵化学工具。基于4，一种I型PRMTs的片段样抑制剂，我们进行了结构-活性关系（SAR）研究，并探索了该支架的三个区域。导致了有效的，选择性的发现的研究，并PRMT4和PRMT6，细胞活性双重抑制剂17（MS049）。与4相比，17在生化和细胞分析中显示PRMT4和PRMT6的效力大大提高。它对PRMT4和PRMT6的选择性高于其他PRMT和其他广泛的表观遗传修饰子和非表观遗传靶标。我们还开发了46（MS049N），在生化和细胞分析中不起作用，作为化学生物学研究的阴性对照。考虑到PRMTs可能重叠的底物特异性，17和46是用于解剖特定的生物学功能以及PRMT4和PRMT6在健康和疾病中异常调节的有价值的化学工具。
• ALIPHATIC ACID AMIDE DERIVATIVE
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：US20220073506A1

  公开（公告）日：2022-03-10

  The present invention relates to a compound represented by formula (1): the compound having antagonist activity against serotonin 5-HT 2A receptors and serotonin 5-HT 7 receptors; or a pharmaceutically acceptable salt of the compound. (In the formula, Z is a nitrogen atom and the like; Y is carbonyl and the like; m and n are 1 and the like; R 1a through R 1d , R 2a through R 2d , and R 4a through R 4d are a hydrogen atom and the like; R 3 is alkyl and the like; and Q is a specific bicyclic group.)

  本发明涉及一种由式（1）表示的化合物：该化合物具有对5-HT2A受体和5-HT7受体的拮抗活性；或者该化合物的药学上可接受的盐。（在式中，Z是氮原子等；Y是羰基等；m和n是1等；R1a至R1d，R2a至R2d和R4a至R4d是氢原子等；R3是烷基等；Q是特定的双环基团。）
• SRC kinase inhibitor compounds
  申请人：Merck & Co., Inc.

  公开号：US06316444B1

  公开（公告）日：2001-11-13

  Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.

  嘌呤类化合物（化学式I），或其药用可接受的盐、水合物、溶剂合物、晶体形式和各个对映体，以及包括这些化合物的药物组合物，它们是酪氨酸激酶酶抑制剂，因此在预防和治疗蛋白质酪氨酸激酶相关疾病方面具有用途，如免疫疾病、高增殖性疾病和其他疾病中，不适当的蛋白质激酶作用被认为起作用，如癌症、血管生成、动脉粥样硬化、移植排斥、类风湿性关节炎和牛皮癣。
• [EN] SUBSTITUED 4-AMINO-1H-IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION<br/>[FR] COMPOSÉS DE 4-AMINO-1H-IMIDAZO[4,5-C] QUINOLÉINE SUBSTITUÉS ET PROCÉDÉS AMÉLIORÉS POUR LEUR PRÉPARATION
  申请人：INNATE TUMOR IMMUNITY INC

  公开号：WO2020037094A1

  公开（公告）日：2020-02-20

  Improved methods and intermediates thereof for preparing substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds are described. These compounds are useful as NLRP3 modulators.

  描述了用于制备取代的4-氨基-1H-咪唑[4,5-c]喹啉化合物的改进方法和中间体。这些化合物可用作NLRP3调节剂。